Table 5 Differences in responder vs non-responder subjects (binary variables)
From: Predicting responsiveness to GLP-1 pathway drugs using real-world data
Features | Number of responders (% of total) | False Discovery Rate (FDR) | |
|---|---|---|---|
Sex | Female | 1674(42.8%) | 9.70E-02 |
Male | 1773(44.9%) | ||
Hispanic ethnicity | No | 3349(43.8%) | 9.42E-01 |
Yes | 98(44.3%) | ||
Race | Africa American | 648(46.8%) | 3.41E-02 |
Non-Africa American | 2799(43.3%) | ||
White | 2688(43.4%) | 1.60E-01 | |
Non-White | 759(45.6%) | ||
Asian | 46(30.8%) | 4.02E-03 | |
Non-Asian | 3401(44.1%) | ||
Other | 74(50.3%) | 1.88E-01 | |
Non-Other | 3373(43.7%) | ||
Chronic kidney disease | Yes | 425(39.7%) | 8.05E-03 |
No | 3022(44.5%) | ||
Cardiomyopathy | Yes | 137(40.1%) | 2.35E-01 |
No | 3310(44.0%) | ||
Heart failure | Yes | 251(38.3%) | 7.58E-03 |
No | 3196(44.3%) | ||
Hypertension | Yes | 2494(44.8%) | 1.99E-02 |
No | 953(41.6%) | ||
Arthritis | Yes | 609(42.1%) | 1.91E-01 |
No | 2838(44.3%) | ||
Gastric bypass | Yes | 69(46.6%) | 5.83E-01 |
No | 3378(43.8%) | ||
Bowel resection | Yes | 33(40.2%) | 6.01E-01 |
No | 3414(43.9%) | ||
Retinopathy | Yes | 137(41.1%) | 3.71E-01 |
No | 3310(44.0%) | ||
insulin | Yes | 1017(50.1%) | 6.04E-10 |
No | 2430(41.7%) | ||
Metformin | Yes | 2130(44.5%) | 2.80E-02 |
No | 1317(42.2%) | ||
Sulfonylureas | Yes | 1359(44.7%) | 3.29E-01 |
No | 2088(43.36%) | ||
Thiazolidinediones | Yes | 289(37.3%) | 3.81E-04 |
No | 3158(44.6%) |